Has Wassim Labaki, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,373 in general payments to Wassim Labaki, MD across 19 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Wassim Labaki, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Wassim Labaki, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Wassim Labaki, MD

Pulmonary Disease · Ann Arbor, MINPI 1992061816

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Inogen, Inc. accounts for 82.4% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $12,522, more than ten times the $246 reported in 2019.

$13,373in general payments, 2019–2025

Across 19 payments — averaging $703.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Inogen, Inc.$11K
Verona Pharma, Inc.$2K
Konica Minolta Healthcare Americas, Inc$500
Pulmonx Corporation$246
Astrazeneca UK Limited$105

$589,655in research payments, 2019–2025

Across 36 payments — averaging $16,379 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$520K
Verona Pharma, Inc.$67K
Sanofi$2K

What the payments were for

Consulting fees$4,25032%
Speaking & faculty fees$6,25047%
Travel & lodging$1,82214%
Food & beverage$1,0518%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Inogen, Inc.	11	$11,022
Verona Pharma, Inc.	1	$1,500
Konica Minolta Healthcare Americas, Inc	1	$500
Pulmonx Corporation	3	$246
Astrazeneca UK Limited	3	$105

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,373 in reported general payments places this provider in the 85th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan →

Medicare billing

Part B allowed, 2024

$21,430

Medicare patients

Services billed

186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	48	$59,028
Stiolto RespimatTiotropium Br/Olodaterol Hcl	41	$35,568
Breztri AerosphereBudesonide/Glycopyr/Formoterol	29	$29,203
Spiriva RespimatTiotropium Bromide	24	$27,630
Breo ElliptaFluticasone/Vilanterol	12	$13,905
Spiriva HandihalerTiotropium Bromide	12	$13,313
Advair HfaFluticasone Propion/Salmeterol	12	$8,807
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	13	$7,045
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate	11	$5,427
Advair DiskusFluticasone Propion/Salmeterol	15	$4,823
Striverdi RespimatOlodaterol Hcl	13	$3,155
Albuterol Sulfate HfaAlbuterol Sulfate	53	$2,901
Azithromycin	68	$1,229
Ventolin HfaAlbuterol Sulfate	14	$876
Montelukast Sodium	15	$458

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Ann Arbor

Meilan HanAnn Arbor$779K
Njira LugogoAnn Arbor$741K
Justin OldhamAnn Arbor$392K
Kevin FlahertyAnn Arbor$328K
Jose de CardenasAnn Arbor$115K
Timothy BlackwellAnn Arbor$99K
Philip ChoiAnn Arbor$54K
Jeanette BrownAnn Arbor$38K
Jeffrey CurtisAnn Arbor$37K
Vibha LamaAnn Arbor$26K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →